Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI), a Delaware corporation and emerging growth company, filed this Form 8-K on March 28, 2024. The report details amendments to convertible promissory notes entered into previously on March 8, 2024, with an investor to settle an unasserted claim.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. The specific financial instruments involved in this report are:
- First Note: $2.0 million convertible promissory note purchased by the investor for cash.
- Second Note: $1.5 million convertible note issued in settlement of an unasserted claim.
- Total Note Value: $3.5 million.
Debt and liquidity metrics beyond the specific terms of these notes are not disclosed in this filing.
Material Changes
On March 28, 2024, the Company amended the terms of the $3.5 million in convertible notes (the "2024 Notes") as follows:
- Conversion Price Adjustment: The conversion price will remain at the Initial Conversion Price for the first 180 days. Thereafter, it resets to 94.0% of the 10-day volume-weighted average price (VWAP) ending on the 180th day.
- Mandatory Conversion Triggers: Mandatory conversion is required if the Company completes a financing of at least $8 million in a registered offering, or at least $2 million with a non-affiliated purchaser at an effective price of at least 150% of the initial note conversion price. Conversion occurs at the lower of the then-current conversion price or the effective price of the new financing.
- Registration Rights: The Company must file a registration statement within five business days after the 180th day from the issuance of the notes.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general risks. The primary contingency noted is the settlement of an unasserted claim via the issuance of the Second Note. The amendments introduce specific conditions under which the debt will convert to equity, impacting future capital structure.
Investor Verification Checklist
- Verify the current trading price of CLDI common stock to assess the potential dilution impact of the 94.0% reset conversion price after 180 days.
- Confirm the status of the "unasserted claim" settled by the $1.5 million Second Note to understand the nature of the liability.
- Monitor upcoming financing activities to determine if the mandatory conversion triggers ($8M registered or $2M non-affiliated at 150% price) are met.
- Review the full text of Exhibits 10.1 and 10.2 for omitted confidential details regarding the note terms.